Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;42(12):1514-1524.
doi: 10.1002/pd.6232. Epub 2022 Sep 18.

Impact of variation in practice in the prenatal reporting of variants of uncertain significance by commercial laboratories: Need for greater adherence to published guidelines

Melissa Cornthwaite  1 , Kelly Turner  1 , Linlea Armstrong  1 , Cornelius F Boerkoel  1 , Caitlin Chang  1 , Anna Lehman  1 , Sarah M Nikkel  1 , Millan S Patel  1 , Margot Van Allen  1 , Sylvie Langlois  1
Affiliations

Impact of variation in practice in the prenatal reporting of variants of uncertain significance by commercial laboratories: Need for greater adherence to published guidelines

Melissa Cornthwaite et al. Prenat Diagn. 2022 Nov.

Abstract

Objective: To evaluate the impact of implementing commercial whole exome sequencing (WES) and targeted gene panel testing in pregnancies with fetal anomalies.

Methods: A retrospective chart review of 124 patients with sequencing performed by commercial laboratories.

Results: The diagnostic yield of WES and panel testing was 21.5% and 26%, respectively, based on likely pathogenic (LP) or pathogenic (P) variants. Forty-two percent of exomes and 32% of panels analysed had one or more variants of uncertain significance (VUS) reported. A multidisciplinary in-depth review of the fetal phenotype, disease phenotype, variant data, and, in some patients, additional prenatal or postnatal investigations increased the diagnostic yield by 5% for exome analysis and 6% for panel analysis.

Conclusions: The diagnostic yield of WES and panel testing combined was 23% based on LP and P variants. Although the reporting of VUS contributed to a 5% increase in diagnostic yield for WES and 6% for panels, the large number of VUS reported by commercial laboratories has significant resource implications. Our results support the need for greater adherence to the recommendations on the prenatal reporting of VUS and the importance of a multidisciplinary approach that brings together clinical and laboratory expertise in prenatal genetics and genomics.

PubMed Disclaimer

References

REFERENCES

    1. Dulgheroff FF, Peixoto AB, Petrini CG, et al. Fetal structural anomalies diagnosed during the first, second and third trimesters of pregnancy using ultrasonography: a retrospective cohort study. Sao Paulo Med J. 2019;137(5):391-400. https://doi.org/10.1590/1516-3180.2019.026906082019
    1. Drukker L, Cavallaro A, Salim I, Ioannou C, Impey L, Papageorghiou AT. How often do we incidentally find a fetal abnormality at the routine third-trimester growth scan? A population-based study. Am J Obstet Gynecol. 2020;223(6):919.e1-919.e13. https://doi.org/10.1016/j.ajog.2020.05.052
    1. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012;367(23):2175-2184. https://doi.org/10.1056/nejmoa1203382
    1. Mellis R, Oprych K, Scotchman E, Hill M, Chitty LS. Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: a systematic review and meta-analysis. Prenat Diagn. 2022;42(6):662-685. https://doi.org/10.1002/pd.6115
    1. Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 2019;393(10173):758-767. https://doi.org/10.1016/s0140-6736(18)32042-7

LinkOut - more resources